<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02631408</url>
  </required_header>
  <id_info>
    <org_study_id>iVRCT1_4</org_study_id>
    <nct_id>NCT02631408</nct_id>
  </id_info>
  <brief_title>Intrawound Vancomycin Powder in Spinal Fusion Surgery</brief_title>
  <acronym>iVRCT</acronym>
  <official_title>Application of Intrawound Vancomycin Powder to Reduce Surgical Site Infections in Spinal Fusion Surgery - A Prospective, Randomized, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orthopedic Hospital Vienna Speising</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orthopedic Hospital Vienna Speising</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vancomycin powder (for solution for Infusion) will be investigated (off-label usage) in
      spinal fusion surgery. The powder will be locally administered into to the wound cavity
      before wound closure.

      Hypothesis: Locally applied vancomycin powder leads to a reduction in postoperative surgical
      site infections
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vancomycin is being widely used as an antibiotic agent for intravenous and topical use. The
      surgical application of vancomycin powder in Austria is limited as there is no powder with
      marketing authorization for intraoperative, intrawound usage. Previous reports widely
      document the application of vancomycin powder for solution for infusion. The powder is not
      soluted, but instead directly spread throughout the wound surface. Limited data is available
      for spinal fusion surgery, mostly retrospective studies. Results were promising, but the low
      evidence level does not allow for a conclusion regarding routine usage. Additional
      randomized, controlled trials are necessary to further investigate this matter.

      This trial aims to investigate Vancomycin powder &quot;Xellia&quot; 1000mg, which has a Marketing
      authorization, in an off-label usage (intrawound, intraoperatively) in spinal fusion surgery.
      The investigational medicinal product will be used unmodified.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SSI rate</measure>
    <time_frame>1 year</time_frame>
    <description>Rate of superficial and deep surgical site infections (according to CDC criteria)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>7 days</time_frame>
    <description>Course of postoperative CRP levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Revision rate</measure>
    <time_frame>1 year</time_frame>
    <description>Revision rate due to surgical site infections</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Spinal Fusion Acquired</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No additional treatment. Routine iv. antibiotic prophylaxis only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vancomycin Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vancomycin powder is applied before wound closure. Routine iv. prophylaxis stays unchanged</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <description>Locally, intrawound applied vancomycin powder</description>
    <arm_group_label>Vancomycin Group</arm_group_label>
    <other_name>Vancomycin Hydrochloride, Powder for Solution for Infusion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Planned TLIF (transforaminal lumbar interbody fusion) or PLIF (posterolateral lumbar
             interbody fusion) surgery

          -  TLIF/PLIF fusion length of one or two motion-segments OR

          -  One motion-segment TLIF/PLIF in conjunction with one motion-segment decompression
             surgery or microscopic disc surgery (microdiscectomy)

          -  Fusions within L1 (first lumbar vertebra) through S1 (sacrum)

          -  Age of 18-years or older

          -  Signed informed consent

        Exclusion Criteria:

          -  Preoperative inflammatory or infectious state (C-reactive protein levels above 10mg/l)

          -  Allergic to vancomycin, teicoplanin or penicillin

          -  Preexisting auto-immune disease with an impaired immune system

          -  Current post-traumatic vertebral injury (e.g. vertebral split fracture)

          -  Preexisting Renal impairment

          -  Preexisting cochlea damage

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philipp Becker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Orthopedic Hospital Speising</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lukas Panzenboeck, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Orthopedic Hospital Speising</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lukas Panzenboeck, MD</last_name>
    <phone>+43(0)1-80182</phone>
    <email>lukas.panzenboeck@oss.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Philipp Becker, MD</last_name>
    <phone>+43(0)1-80182</phone>
    <email>philipp.becker@oss.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Orhopedic Hospital Speising</name>
      <address>
        <city>Vienna</city>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabeth Braeuer, Dr.</last_name>
      <phone>+43(0)1-80182</phone>
      <email>elisabeth.braeuer@oss.at</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2015</study_first_submitted>
  <study_first_submitted_qc>December 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2015</study_first_posted>
  <last_update_submitted>October 3, 2017</last_update_submitted>
  <last_update_submitted_qc>October 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Orthopedic Hospital Vienna Speising</investigator_affiliation>
    <investigator_full_name>Lukas Panzenboeck</investigator_full_name>
    <investigator_title>Dr. Lukas Panzenboeck</investigator_title>
  </responsible_party>
  <keyword>spinal fusion</keyword>
  <keyword>topical antibiotics</keyword>
  <keyword>vancomycin</keyword>
  <keyword>surgical site infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Surgical Wound Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

